Can a specialist prescribe cagrilintide?
Calling someone a specialist does not tell you whether the medicine they offer is approved. Start with this question: “What exactly are you offering me?”
Facts checked September 28, 2026.
There is no approved product yet
The FDA, the US drug regulator, had approved neither cagrilintide nor CagriSema for any US use as of September 28, 2026.
A prescription alone cannot turn cagrilintide into an approved product.
Ask: “What is the exact medicine name? Has the FDA approved it for the use we are discussing?”
If the answer is yes, ask to see its official medicine information, called the label. If a study is offered instead, ask for the study name and how to check it.
An application is a request
The maker submitted a CagriSema approval application in December 2025.
At the September 28, 2026 check, it was still awaiting a decision.
The maker’s forecast was a decision late in 2026, not a promise of approval.
That application concerns the combination, not cagrilintide by itself.
Compounding is not a way around this
Compounding means making a medicine to order, with a pharmacist or doctor preparing it.
Compounding can help a patient when no approved medicine meets that person’s needs.
Federal law rules out cagrilintide as a compounding ingredient, according to the FDA statement checked September 28, 2026.
No compounded medicine has FDA approval.
Compounded medicines reach patients without a prior FDA review of safety, quality, or whether the medicine works.
Where studies fit
ClinicalTrials.gov is a free US government record of studies.
Its September 28, 2026 records included cagrilintide studies recruiting at US locations.
A listing does not mean the government recommends the study, and it may stop accepting volunteers.
Expanded access means asking to receive a medicine still being studied, outside a study.
It is only a possible option for a serious or life-threatening illness when no suitable treatment is available and joining a study is not possible.
Your doctor and the FDA must judge whether your illness meets those conditions.
Ask your doctor: “Could this apply to my illness?” A search for weight care alone cannot answer that.
On September 28, 2026, no cagrilintide expanded-access programme was listed.
A doctor’s request for one patient may not appear in the public records, so no listing does not mean access is impossible.
Ask your doctor to explain whether such a request is relevant to your care.
Find the FDA pages and government study list